According to the “AstraZeneca’s Impact on Türkiye” Report, which reveals AstraZeneca’s impact on the pharmaceutical industry and our country over the past quarter century with the support of EY Türkiye, one of the leading consulting companies, AstraZeneca is the company that initiated the most clinical research in our country in 2022 and 2023, while conducting 90 active clinical research studies with a clinical research team of approximately 100 people. AstraZeneca has realized a significant increase in clinical research investments since 2020 and increased its total investment amount to 1.1 billion TL. 65 percent of the clinical research conducted by AstraZeneca in our country consists of studies in the field of oncology.”
“We invested more than 500 million TL last year alone”
Stating that increased investment in clinical research enables accelerated access to innovative treatments and knowledge in countries that attract investment, Pharm. Serkan Barış, Country President of AstraZeneca Türkiye said, “While we continue to grow steadily every year with the strength we derive from our deep-rooted experience, we make significant contributions to health policy priorities as the pharmaceutical company that initiated the highest number of clinical trials in Türkiye. In 2023, we invested 570 million TL in clinical research. Our investments in the last four years exceeded TL 1 billion. On the other hand, the majority of our active clinical research in Türkiye is in the field of oncology. In this way, we make a significant contribution to tracking new developments in the treatment of challenging diseases such as cancer, providing patients with early access to innovative treatments and achieving better health outcomes. We are proud of our contribution to the production of the most up-to-date information in our treatment areas and to the development of the healthcare workforce and infrastructure by expanding clinical research studies.”
“We aim to make Türkiye a leader in clinical research in the region”
Emphasizing that AstraZeneca is among the companies conducting the highest number of clinical trials in Türkiye, Dr. Deniz Ertürk Erem, Medical Director of AstraZeneca Türkiye, said: “We aim to be the first in Türkiye in the field of clinical research and to contribute to Türkiye’s leading position in the region. In addition to our clinical research investments, which have increased substantially in recent years, we also demonstrate our determination in this field with our corporate collaborations. As a matter of fact, AstraZeneca was the pharmaceutical company that initiated the highest number of new clinical research studies in Türkiye in 2022 and 2023. We provide a lot of support for clinical research in our country’s healthcare ecosystem, especially universities and physician associations. With our strategic partnership with Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital and Adana City Training and Research Hospital, we aim to increase the number of clinical studies and enable more patients to access innovative treatments by including them in clinical studies. We also collaborate with a total of 95 centers in 38 provinces across Türkiye to generate and support the generation of real-life data. In the last 5 years, we have contributed to the production of more than 20 real-life data in many disease areas such as heart failure, chronic kidney disease, asthma and lung cancer.”
